Navigating Uncharted Territory in Surgical Innovation: A systematic review of non-standard Metabolic Bariatric Surgery procedures.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 41992421.
- Also identified by DOI 10.1093/bjs/znag047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Surgical innovation often outpaces robust evaluation. This study used metabolic bariatric surgery (MBS), a field of high-intensity innovation, as a case study to evaluate reporting standards and ethical oversight for experimental procedures within surgery. We conducted a systematic review in accordance with PRISMA 2020 guidelines. We searched PubMed/MEDLINE, Web of Science, Scopus, Cochrane Library, and Embase from January 2000 to December 2024 using terms related to metabolic bariatric surgery, surgical innovation, and non-standard intestinal bypass procedures. We included original studies reporting first-in-human or early clinical series of non-standard primary MBS involving significant intestinal modification, and excluded reviews, editorials, conference abstracts, revisional surgery, purely restrictive procedures, and device-based interventions. Two reviewers independently screened studies, extracted data on publication timing, patient numbers, follow-up, ethical approval, and trial registration, and assessed risk of bias using the Newcastle-Ottawa Scale, Joanna Briggs Institute checklist, and ROBINS-I tool. From 57 included studies (10,754 patients), the median time from first human operation to publication was 5 years (IQR 3-8 years). The median initial cohort size was 39 patients (range 1-1074 patients). Institutional review board or ethical approval was reported in 47/57 studies (82%), while prospective clinical trial registration was documented in only 6/57 studies (11%). Methodological quality was low (mean Newcastle-Ottawa Scale score 5.0/9), with 56 of 57 studies judged at high risk of bias. Out of 57, studies, only 15 (26%) reported outcomes at ≥3 years, and 8 studies (14%) at ≥5 years. This MBS case study reveals delayed publication and a widespread lack of prospective trial registration, exposing over 10,000 patients to experimental procedures outside a transparent research framework. These findings highlight a systemic failure in surgical innovation governance and underscore an urgent need for a cultural shift towards mandatory, prospective oversight frameworks to ensure patient safety and credible evidence generation.